[Case]2型糖尿病に対しオマリグリプチン(omarigliptin)内服による治療を開始して1年10ヶ月経過したところでBPを発症した。
[IMG]診断時の病変:全身に掻痒感を伴う浮腫性紅斑の多発
Uploaded on December 21, 2019.
参考文献
1. Kridin K, Bergman R: Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes. Estimating the risk of the new agents and characterizing the patients. JAMA Dermatol. 2018; 154(10): p1152-p1158 doi: 10.1001/jamadelmatol.2018.2352.
2. Benzaquen M, Borradori L, et al: Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case -control study from France and Switzerland. J Am Acad Dermatol. 2018: p1090-p1096
3. Arai M, Shirakawa J, et al: Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproprtionality analysis based on the Japanese adverse drug event report database. Diabetes Care. 2018: e1-e3.
4. Ujiie H, et al: HLA-DQB1*3:01 as a biomarker for genetic susceptibility to bullous pemphigoid induce by DPP-4 inhibitors. J Invest Dermatol. 2018; 138: p1201-p1204
5. Izumi K, Nishie W, et al: Autoantibody profile dif- ferentiates between inflammatory and non-inflammatory bullous pemphigoid, J Invest Dermatol. 2016; 136: p2201―p2210.
5.氏家英之, 岩田浩明, et al: 類天疱瘡(後天性表皮水疱症を含む)診療ガイドライン. 日皮雑誌. 2017; 127(7): p1483-p1521
個々の症例のデータ、画像の引用または転載を一切許可しない